| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | GABA A receptor subunit alpha 4, GABRA4, Gamma aminobutyric acid A receptor Alpha 4, Gamma-aminobutyric acid receptor subunit alpha-4, GBRA4_HUMAN |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 410-450 (Cytoplasmic C-terminus) of rat GABA-A-Receptor Alpha 4 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
The GABA-A receptor alpha 4 subunit (GABRA4) is a key component of the GABA-A receptor complex, the primary mediator of fast inhibitory neurotransmission in the central nervous system. As part of the ligand-gated ion channel superfamily, GABRA4 contributes to tonic inhibition, particularly in the thalamus and hippocampus—regions essential for cognition, memory, and seizure regulation.
Dysregulation of GABRA4 has been strongly linked to epilepsy and pharmacoresistance to antiepileptic drugs, highlighting its role in maintaining neural circuit stability. Beyond epilepsy, emerging evidence suggests that GABRA4 dysfunction may contribute to the pathophysiology of neurodegenerative diseases by disrupting inhibitory-excitatory balance, promoting network hyperexcitability, and impairing synaptic plasticity.
These mechanisms are increasingly recognized in conditions such as Alzheimer’s disease, where altered GABAergic signaling is associated with cognitive decline and neuronal vulnerability. As a result, GABRA4 is gaining attention as a potential biomarker and therapeutic target in neurodegeneration.
Advancing our understanding of GABRA4’s role in inhibitory signaling may unlock new strategies for early intervention and disease modification in disorders characterized by GABAergic dysfunction.
A 1:100 dilution of SMC-489 was sufficient for detection of GABA-A R, Alpha4 in 20 µg of mouse brain lysate by ECL immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-489D — Size: 100 ug: GABAA Receptor Alpha 4 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D, RRID: AB_2702513)
- SMC-489D-A390 — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-A390, RRID: AB_2702514)
- SMC-489D-A488 — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-A488, RRID: AB_2702515)
- SMC-489D-A594 — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-A594, RRID: AB_2702517)
- SMC-489D-APC — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-APC, RRID: AB_2702523)
- SMC-489D-BI — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-BI, RRID: AB_2702524)
- SMC-489D-FITC — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-FITC, RRID: AB_2702525)
- SMC-489D-HRP — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-HRP, RRID: AB_2702526)
- SMC-489D-PCP — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-PCP, RRID: AB_2702528)
- SMC-489D-RPE — Size: 100 ug: GABAA Receptor Alpha 4 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489D-RPE, RRID: AB_2702529)
- SMC-489S — Size: 12 ug: GABAA Receptor Alpha 4 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-489S, RRID: AB_2702513)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Macdonald R.L., Olsen R.W. (1993) Annu Rev Neurosci. 17: 569-602.
3. Grabenstatter H.L., et al. (2014) Epilepsia. 55(11): 1826-1833.
4. Bethmann K., Fritschy J.M., Brandt C., Loscher W. (2008) Neurbiol Dis. 31(2): 169-187.